These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

885 related articles for article (PubMed ID: 22686415)

  • 21. Basal insulin and cardiovascular and other outcomes.
    Ceriello A
    N Engl J Med; 2012 Nov; 367(18):1762-3; author reply 1763-4. PubMed ID: 23113496
    [No Abstract]   [Full Text] [Related]  

  • 22. Basal insulin and cardiovascular and other outcomes.
    Schernthaner G; Currie CJ
    N Engl J Med; 2012 Nov; 367(18):1762; author reply 1763-4. PubMed ID: 23113495
    [No Abstract]   [Full Text] [Related]  

  • 23. Basal insulin and cardiovascular and other outcomes.
    Vigneri R; Vigneri P; Frittitta L
    N Engl J Med; 2012 Nov; 367(18):1761-2; author reply 1763-4. PubMed ID: 23113494
    [No Abstract]   [Full Text] [Related]  

  • 24. Rosuvastatin in older patients with systolic heart failure.
    Kjekshus J; Apetrei E; Barrios V; Böhm M; Cleland JG; Cornel JH; Dunselman P; Fonseca C; Goudev A; Grande P; Gullestad L; Hjalmarson A; Hradec J; Jánosi A; Kamenský G; Komajda M; Korewicki J; Kuusi T; Mach F; Mareev V; McMurray JJ; Ranjith N; Schaufelberger M; Vanhaecke J; van Veldhuisen DJ; Waagstein F; Wedel H; Wikstrand J;
    N Engl J Med; 2007 Nov; 357(22):2248-61. PubMed ID: 17984166
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of 1-year treatment with metformin on metabolic and cardiovascular risk factors in non-diabetic upper-body obese subjects with mild glucose anomalies: a post-hoc analysis of the BIGPRO1 trial.
    Fontbonne A; Diouf I; Baccara-Dinet M; Eschwege E; Charles MA
    Diabetes Metab; 2009 Nov; 35(5):385-91. PubMed ID: 19665415
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
    Sasaki J; Ikeda Y; Kuribayashi T; Kajiwara K; Biro S; Yamamoto K; Ageta M; Kobori S; Saikawa T; Otonari T; Kono S
    Clin Ther; 2008 Jun; 30(6):1089-101. PubMed ID: 18640465
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cardiovascular and Other Outcomes Postintervention With Insulin Glargine and Omega-3 Fatty Acids (ORIGINALE).
    ORIGIN Trial Investigators
    Diabetes Care; 2016 May; 39(5):709-16. PubMed ID: 26681720
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comments on ORIGIN trial.
    Mazzucchelli C; Bordone C; Maggi D; Cordera R
    Nutr Metab Cardiovasc Dis; 2013 Aug; 23(8):e33-4. PubMed ID: 23786822
    [No Abstract]   [Full Text] [Related]  

  • 29. Effects of dalcetrapib in patients with a recent acute coronary syndrome.
    Schwartz GG; Olsson AG; Abt M; Ballantyne CM; Barter PJ; Brumm J; Chaitman BR; Holme IM; Kallend D; Leiter LA; Leitersdorf E; McMurray JJ; Mundl H; Nicholls SJ; Shah PK; Tardif JC; Wright RS;
    N Engl J Med; 2012 Nov; 367(22):2089-99. PubMed ID: 23126252
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis.
    Wanner C; Krane V; März W; Olschewski M; Mann JF; Ruf G; Ritz E;
    N Engl J Med; 2005 Jul; 353(3):238-48. PubMed ID: 16034009
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Incidence of cardiovascular events in which 2 thiazolidinediones are used as add-on treatments for type 2 diabetes mellitus in a Taiwanese population.
    Wang CC; Chen WL; Kao TW; Chang YW; Loh CH; Chou CC
    Clin Ther; 2011 Dec; 33(12):1904-13. PubMed ID: 22118894
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of insulin glargine and n-3FA on carotid intima-media thickness in people with dysglycemia at high risk for cardiovascular events: the glucose reduction and atherosclerosis continuing evaluation study (ORIGIN-GRACE).
    Lonn EM; Bosch J; Diaz R; Lopez-Jaramillo P; Ramachandran A; Hâncu N; Hanefeld M; Krum H; Ryden L; Smith S; McQueen MJ; Dyal L; Yusuf S; Gerstein HC;
    Diabetes Care; 2013 Sep; 36(9):2466-74. PubMed ID: 23564916
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of ramipril on the incidence of diabetes.
    ; Bosch J; Yusuf S; Gerstein HC; Pogue J; Sheridan P; Dagenais G; Diaz R; Avezum A; Lanas F; Probstfield J; Fodor G; Holman RR
    N Engl J Med; 2006 Oct; 355(15):1551-62. PubMed ID: 16980380
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Incidence of atrial fibrillation in a population with impaired glucose tolerance: the contribution of glucose metabolism and other risk factors. A post hoc analysis of the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research trial.
    Latini R; Staszewsky L; Sun JL; Bethel MA; Disertori M; Haffner SM; Holman RR; Chang F; Giles TD; Maggioni AP; Rutten GE; Standl E; Thomas L; Tognoni G; Califf RM; McMurray JJ
    Am Heart J; 2013 Nov; 166(5):935-40.e1. PubMed ID: 24176451
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus: the AleCardio randomized clinical trial.
    Lincoff AM; Tardif JC; Schwartz GG; Nicholls SJ; Rydén L; Neal B; Malmberg K; Wedel H; Buse JB; Henry RR; Weichert A; Cannata R; Svensson A; Volz D; Grobbee DE;
    JAMA; 2014 Apr; 311(15):1515-25. PubMed ID: 24682069
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of succinobucol (AGI-1067) after an acute coronary syndrome: a randomised, double-blind, placebo-controlled trial.
    Tardif JC; McMurray JJ; Klug E; Small R; Schumi J; Choi J; Cooper J; Scott R; Lewis EF; L'Allier PL; Pfeffer MA;
    Lancet; 2008 May; 371(9626):1761-8. PubMed ID: 18502300
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Marine n-3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer.
    Manson JE; Cook NR; Lee IM; Christen W; Bassuk SS; Mora S; Gibson H; Albert CM; Gordon D; Copeland T; D'Agostino D; Friedenberg G; Ridge C; Bubes V; Giovannucci EL; Willett WC; Buring JE;
    N Engl J Med; 2019 Jan; 380(1):23-32. PubMed ID: 30415637
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Voglibose for prevention of type 2 diabetes mellitus: a randomised, double-blind trial in Japanese individuals with impaired glucose tolerance.
    Kawamori R; Tajima N; Iwamoto Y; Kashiwagi A; Shimamoto K; Kaku K;
    Lancet; 2009 May; 373(9675):1607-14. PubMed ID: 19395079
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of polyunsaturated vegetable oils on adiponectin levels, glycaemia and blood lipids in individuals with type 2 diabetes: a randomised, double-blind intervention study.
    Müllner E; Plasser E; Brath H; Waldschütz W; Forster E; Kundi M; Wagner KH
    J Hum Nutr Diet; 2014 Oct; 27(5):468-78. PubMed ID: 24138546
    [TBL] [Abstract][Full Text] [Related]  

  • 40. International Variation in Outcomes Among People with Cardiovascular Disease or Cardiovascular Risk Factors and Impaired Glucose Tolerance: Insights from the NAVIGATOR Trial.
    Harumi Higuchi Dos Santos M; Sharma A; Sun JL; Pieper K; McMurray JJ; Holman RR; Lopes RD
    J Am Heart Assoc; 2017 Jan; 6(1):. PubMed ID: 28087508
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 45.